Humacyte, Inc.
HUMA · XNASCIK 1818382fmd_1214BKDQ2MPYSBA2ZM4H9JEQMGManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 0 | 2 |
| Cost of revenue | – | – | – | – | 0 | 10 |
| Gross profit | – | – | – | – | 0 | (8) |
| Research and development | 54 | 61 | 63 | 77 | 89 | 69 |
| Total operating expenses | 66 | 82 | 86 | 100 | 114 | – |
| Operating income | (65) | (81) | (85) | (100) | (114) | (108) |
| Interest expense | 2 | 4 | 6 | 7 | 9 | 11 |
| Interest and investment income | 0 | 0 | 3 | 5 | 4 | 3 |
| Other non-operating income (expense) | (2) | 55 | 73 | (11) | (34) | 67 |
| Income before taxes | – | – | – | – | – | (41) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | (41) |
| Net income | (67) | (26) | (12) | (111) | (149) | (41) |